Eagle Strategies’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$934K Buy
3,678
+295
+9% +$68.8K 0.09% 151
2026
Q1
$827K Buy
3,383
+15
+0.4% +$3.49K 0.1% 140
2025
Q4
$697K Buy
3,368
+5
+0.1% +$989 0.09% 144
2025
Q3
$624K Sell
3,363
-412
-11% -$70.6K 0.08% 148
2025
Q2
$577K Sell
3,775
-167
-4% -$25.7K 0.09% 141
2025
Q1
$654K Buy
3,942
+19
+0.5% +$2.97K 0.11% 127
2024
Q4
$567K Buy
3,923
+196
+5% +$30.4K 0.1% 131
2024
Q3
$604K Buy
3,727
+50
+1% +$7.97K 0.11% 123
2024
Q2
$537K Buy
3,677
+983
+36% +$146K 0.1% 125
2024
Q1
$426K Sell
2,694
-895
-25% -$142K 0.09% 176
2023
Q4
$563K Buy
3,589
+63
+2% +$9.66K 0.12% 115
2023
Q3
$549K Buy
3,526
+15
+0.4% +$2.48K 0.14% 110
2023
Q2
$581K Buy
3,511
+502
+17% +$81K 0.14% 107
2023
Q1
$467K Sell
3,009
-388
-11% -$62.7K 0.12% 115
2022
Q4
$600K Sell
3,397
-40
-1% -$6.91K 0.18% 96
2022
Q3
$561K Buy
3,437
+962
+39% +$163K 0.29% 62
2022
Q2
$439K Sell
2,475
-612
-20% -$109K 0.16% 96
2022
Q1
$547K Buy
3,087
+926
+43% +$158K 0.21% 80
2021
Q4
$370K Buy
+2,161
New +$354K 0.14% 108

Other funds holding JNJ

Eagle Strategies's JNJ Position: Q2 2026 in Review

Eagle Strategies increased its Johnson & Johnson (JNJ) stake by 8.7% in Q2 2026, buying an estimated $68.8K and bringing the position to 3,678 shares worth $934K. The position accounts for 0.09% of the portfolio, ranked #151.

Eagle Strategies first reported a position in JNJ in Q4 2021 and has held it in 19 quarters since. 2,503 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Eagle Strategies held 3,678 shares of Johnson & Johnson worth $934K as of Q2 2026.
  • Eagle Strategies bought 295 Johnson & Johnson shares in Q2 2026, an estimated $68.8K.
  • Johnson & Johnson made up 0.09% of Eagle Strategies's portfolio in Q2 2026, its #151 holding.
  • Eagle Strategies first reported a position in Johnson & Johnson in Q4 2021 and has held it in 19 quarters since.
  • 2,503 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Eagle Strategies's 13F filing for Q2 2026, filed 21 Jul 2026.